Platelet aggregation devices market seen reaching $2.93 billion by 2030

The Business Research Company says the global platelet aggregation devices market is set to grow from $1.04 billion in 2025 to $2.94 billion by 2030, driven by rising cardiovascular disease, cancer and diabetes cases, plus demand for faster platelet function testing. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - Platelet aggregation devices help diagnose and manage clotting disorders, assess platelet function and evaluate antiplatelet therapy. - The market’s projected jump to $2.94 billion by 2030 signals stronger demand for blood-clotting diagnostics across hospitals, labs and research settings. - Rising cases of cardiovascular disease, cancer and diabetes are increasing the need for early thrombotic-risk detection and treatment monitoring.

What happened: - The Business Research Company published a report on the platelet aggregation devices market on Aug. 24, 2026. - The report puts the market at $1.04 billion in 2025 and $1.31 billion in 2026. - The forecast calls for a rise to $2.94 billion by 2030. - The report says the market will grow at a 25.4% CAGR from 2025 to 2026 and at a 22.5% CAGR through 2030.

The details: - Growth drivers in the report include wider use of antiplatelet therapies, more coagulation testing, expansion of clinical diagnostic labs and advances in hematology diagnostics. - Future demand is expected to come from personalized medicine, advanced diagnostic tools, rapid platelet function tests, blood-disorder research and diagnostic technology upgrades. - Key product trends include automated platelet function analyzers, high-throughput testing systems, digital data management, multi-channel aggregation devices and a greater focus on diagnostic accuracy. - The report defines platelet aggregation devices as tools that measure how quickly and extensively platelets clump together. - The report says these devices are used in clinical and research environments. - The report lists North America as the largest market in 2025. - The report projects Asia-Pacific as the fastest-growing region in the coming years. - Covered regions include Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and technology and future-trend analysis.

Between the lines: - The forecast suggests platelet testing is moving from a niche diagnostic category toward broader use as chronic disease burdens rise. - The emphasis on automation, high-throughput systems and digital management points to demand for faster workflows and more standardized results in lab settings. - The report’s regional split suggests mature markets still dominate today, but growth momentum is shifting toward Asia-Pacific. - IARC data cited in the release underline the scale of the cancer burden, with about 20 million new cases and 9.7 million deaths worldwide in 2022. - IARC projects new cancer cases could rise 77% by 2050 to more than 35 million a year.

What's next: - The market is expected to keep expanding as healthcare systems adopt faster platelet function testing and more advanced diagnostic platforms. - Additional demand may follow if personalized medicine and blood-disorder research continue to scale. - The company is offering a free sample of the report and access to the full market report through its website.

The bottom line: - Platelet aggregation devices are moving into a higher-growth diagnostics segment as chronic disease rates, testing demand and lab automation all climb.